Phase i study of tilorone, a non-marrow depressing antitumor agent
Wampler, G.L.; Kuperminc, M.; Regelson, W.
Cancer ChemoTherapy Reports 57(2): 209-217
1973
ISSN/ISBN: 0069-0112 PMID: 4742500 Document Number: 66262
Document emailed within 1 workday
Related Documents
Tiagotin, I.V.; Polotskiĭ, A.E.; Vakhitov, T.I.; Tutova, I.I.; Rybakova, L.P. 1998: Experimental study of the biopreparation Lymphotilin as an antiproliferative and antitumor agent Voprosy Onkologii 44(1): 92-96Tura, S.; Mazza, P.; Gherlinzoni, F.; Zinzani, P.L.; Poletti, G.; Visani, G.; Lemoli, R.M.; Bandini, G.; Cavo, M.; Galieni, P. 1988: Phase Ii study with a new alkylating agent (PTT-119) in lymphoid malignancies Haematologica 73(6): 503-508
Sampi, K.; Honda, T.; Hayashi, Y.; Hattori, M. 1983: Phase Ii study of a new anthraquinone antineoplastic agent, mitoxantrone, in hematological malignancies Gan to Kagaku Ryoho. Cancer and ChemoTherapy 10(6): 1538-1539
Bianco, V.; Rozzi, A.; Tonini, G.; Santini, D.; Magnolfi, E.; Vincenzi, B.; D'Angelillo, R.; Marchei, P. 2002: Gemcitabine as single agent chemotherapy in elderly patients with stages III-IV non-small cell lung cancer (NSCLC): a phase Ii study Anticancer Research 22(5): 3053-3056
Philip, P.A.; Thompson, C.H.; Carmichael, J.; Rea, D.; Mitchell, K.; Taylor, D.J.; Stuart, N.S.; Dennis, I.; Rajagopalan, B.; Ganesan, T. 1993: A phase I study of the left-shifting agent BW12C79 plus mitomycin C and the effect on the skeletal muscle metabolism using 31P magnetic resonance spectroscopy Cancer Research 53(23): 5649-5653
Rainey, J.M. 1978: Cis-dichlorodiammineplatinum (II): a new antitumor agent Arizona Medicine 35(7): 462-463
Douay, L.; Gorin, N.C.; David, R.; Stachowiak, J.; Salmon, C.; Najman, A.; Duhamel, G. 1982: Study of granulocyte-macrophage progenitor (CFUc) preservation after slow freezing of bone marrow in the gas phase of liquid nitrogen Experimental Hematology 10(4): 360-366
Lee, S.H.; Chiu, H.; Rinderknecht, E.; Sabo, W.; Stebbing, N. 1983: Importance of treatment regimen of interferon as an antitumor agent Cancer Research 43(9): 4172-4175
Banovic, P.; Stankov, S.; Vranjes, N.; Zurkovic, O.; Capo, I.; Lalosevic, D. 2018: Drug repurposing: mebendazole as effective antitumor agent. Are we seeing the whole story? Journal of BUON: Official Journal of the Balkan Union of Oncology 23(6): 1904-1911
Gridelli, C.; Frontini, L.; Barletta, E.; Rossi, A.; Barzelloni, M.L.; Scognamiglio, F.; Guida, C.; Gatani, T.; Fiore, F.; De Bellis, M.; Marfella, A.; Manzione, L. 2000: Single agent docetaxel plus granulocyte-colony stimulating factor (G-CSF) in previously treated patients with advanced non small cell lung cancer. A phase II study and review of the literature Anticancer Research 20(2b): 1077-1084
Stoppa, A.M.; Blaise, D.; Viens, P.; Baume, D.; Mannoni, P.; Novakovitch, G.; David, F.A.; Yver, A.; Maraninchi, D. 1994: Phase I study of in vivo lenograstim (rHuG-CSF) for stem cell collection demonstrates improved neutrophil recovery after autologous bone marrow transplantation Bone Marrow Transplantation 13(5): 541-547
Petersen, F.B.; Buckner, C.D.; Appelbaum, F.R.; Sanders, J.E.; Bensinger, W.I.; Storb, R.; Deeg, H.J.; Witherspoon, R.P.; Sullivan, K.M.; Clift, R.A. 1992: Etoposide, cyclophosphamide and fractionated total body irradiation as a preparative regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study Bone Marrow Transplantation 10(1): 83-88
McGovren, J.P.; Neil, G.L.; Denlinger, R.H.; Hall, T.L.; Crampton, S.L.; Swenberg, J.A. 1979: Chronic cardiotoxicity studies in rabbits with 7-con-O-methylnogarol, a new anthracycline antitumor agent Cancer Research 39(12): 4849-4855
Li, L.H.; Swenson, D.H.; Schpok, S.L.; Kuentzel, S.L.; Dayton, B.D.; Krueger, W.C. 1982: CC-1065 (NSC 298223), a novel antitumor agent that interacts strongly with double-stranded DNA Cancer Research 42(3): 999-1004
Friedman, J.; Moore, E.C.; Hall, S.W.; Loo, T.L. 1979: Enzymatic assay for the antitumor agent-N-(phosphonacetyl)-L-aspartic acid (PALA) Cancer Treatment Reports 63(1): 85-88
Nemunaitis, J.; Ross, M.; Meisenberg, B.; O'Reilly, R.; Lilleby, K.; Buckner, C.D.; Appelbaum, F.R.; Buhles, W.; Singer, J.; Peters, W.P. 1994: Phase i study of recombinant human interleukin-1 beta (rhIL-1 beta) in patients with bone marrow failure Bone Marrow Transplantation 14(4): 583-588
Sur, P.; Bag, S.P.; Sur, B.; Khanam, J.A. 1997: Chloroaceto hydroxamic acid as antitumor agent against Ehrlich ascites carcinoma in mice Neoplasma 44(3): 197-201
Fukuda, M.; Arimura, T.; Katayama, K.; Watanabe, H. 1991: Complete response provided by new antitumor agent, MST-16 (sobuzoxane), in a breast cancer with multiple cutaneous metastases Gan to Kagaku Ryoho. Cancer and ChemoTherapy 18(10): 1709-1712
Tsuruo, T.; Oh-hara, T.; Iida, H.; Tsukagoshi, S.; Sato, Z.; Matsuda, I.; Iwasaki, S.; Okuda, S.; Shimizu, F.; Sasagawa, K. 1986: Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines Cancer Research 46(1): 381-385
Wodinsky, I.; Swiniarski, J.K. 1975: Antitumor activity of amygdalin MF (NSC-15780) as a single agent and with beta-glucosidase (NSC-128056) on a spectrum of transplantable rodent tumors Cancer ChemoTherapy Reports 59(5): 939-950